

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: UniDoc Health Corp. (the "Issuer").

Trading Symbol: UDOC

Number of Outstanding Listed Securities: 10,933,350 (as of February 28, 2022)

Date: March 3, 2022

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

UniDoc Health Corp. is a virtual health/telemedicine solutions company. The Issuer's primary offering will be the Virtual Care Solutions Model, a proprietary, customizable, and comprehensive telehealth solution that integrates a range of physical products, web-based services and analytical tools, along with access to

the Issuer's developing network of healthcare providers, pharmacies, and hospitals.

2. Provide a general overview and discussion of the activities of management.

During the month of February 2022, management's activities consisted of:

- Entering into a commercial master distribution agreement with Massachusetts-based AMD Global Telemedicine Inc. ("AMD Global");
- Advancing the Issuer's development of its "H3 Health Cube";
- Appointing Mr. Eric Bacon, President of AMD Global as an advisory board appointee; and
- Filing its interim financial statements and management's discussion and analysis for the nine months period ending December 31, 2021.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

There were no new products or services developed or offered during the month of February 2022.

The Issuer announced that it is in advanced stage development of the "H3 Health Cube", one of the several kiosk models under development and is specifically designed to meet Americans with Disabilities Act Standards for Accessible Design and related international equivalents. The H3 cube will provide full privacy, adjustable lighting, modular expandability to accommodate multiple diagnostic technical packages, robust internet connectivity, electrical distribution with water and compressed air or mixed gas options, climate control and enclosure designs suited for either indoor or outdoor environments. The H3 Health Cube has been prototyped and the Issuer plans to commence pilot field studies shortly.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

There were no products or services discontinued during the month of February 2022.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

The Issuer entered into a commercial master distribution agreement with AMD Global pursuant to which AMD Global will be a key supplier to the Issuer of telehealth solutions including virtual care software platforms, integrated medical devices, and telemedicine bundled kits. The products and services will be purposed and integrated into the UniDoc Virtual Care Solutions Model, which will

offer a proprietary, customizable, and comprehensive telehealth solution based on a variety of integrated physical enclosures, kiosks, and related configurable packaging designed to deliver web-based services and analytical tools in combination with access to a developing network of healthcare providers, pharmacies, and hospitals.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

There were no expiry or termination of any contracts or agreements or cancellation of any financing arrangements during the month of February 2022.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

There were no acquisitions by the Issuer or disposition of the Issuer's assets that occurred during the month of February 2022.

8. Describe the acquisition of new customers or loss of customers.

There were no acquisition of new customers or loss of customers during the month of February 2022.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

There were no new developments or effects on intangible products during the month of February 2022.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

There were no employee hirings, terminations or lay-offs during the month of February 2022.

11. Report on any labour disputes and resolutions of those disputes if applicable.

There were no labour disputes during the month of February 2022.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

There were no legal proceedings to which the Issuer became a party during the month of February 2022.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

There was no indebtedness incurred or repaid by the Issuer during the month of February 2022.

14. Provide details of any securities issued and options or warrants granted.

| Security | Number Issued | Details of Issuance | Use of Proceeds ⁽¹⁾ |
|---------------|---------------|---------------------------|--|
| Common Shares | 931,250 | Exercise of Unit Warrants | The Issuer proposes to use the proceeds of \$186,250 to advance its current marketing and awareness campaigns. |
| Warrants | 931,250 | Exercise of Unit Warrants | |

(1) State aggregate proceeds and intended allocation of proceeds.

15. Provide details of any loans to or by Related Persons.

There were no loans made to or by Related Persons during the month of February 2022.

16. Provide details of any changes in directors, officers or committee members.

There were no changes in directors, officers or committee members during the month of February 2022.

Mr. Eric Bacon, President of AMD Global was appointed as an advisory board appointee, effective February 16, 2022.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The trends and risks which are likely to impact the Issuer are disclosed under the heading "Risk Factors" in the Issuer's final long form prospectus dated December 3, 2021, which is available under the Issuer's profile on SEDAR (www.sedar.com).

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated March 3, 2022.

Nina Yii
Name of Director or Senior
Officer

"Nina Yii"
Signature

Chief Financial Officer
Official Capacity

| | | |
|--|---|---|
| Issuer Details Name of Issuer UniDoc Health Corp. | For Month End February 2022 | Date of Report YY/MM/D 22/03/03 |
| Issuer Address 220 - 333 Terminal Avenue | | |
| City/Province/Postal Code Vancouver, British Columbia V6A 4C1 | Issuer Fax No. N/A | Issuer Telephone No. 905-264-8885 |
| Contact Name Nina Yii | Contact Position CFO | Contact Telephone No. 647-881-9140 |
| Contact Email Address nina@acmfirm.ca | Web Site Address https://unidoctor.com/ | |